ADARx Pharmaceuticals Inc. (ADRX)
NASDAQ: ADRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.42B
- EPS (TTM)
- -$6.75
- Dividend yield
- None
- 52-week range
- 12.50 – 23.21
- Day range
- 12.66 – 14.86
- Volume / Avg
- 708.82K / 650.63K
- Beta
- —
- Shares outstanding
- 111.19M
52-week range
ADRX stock today
ADARx Pharmaceuticals (ADRX) closed at $12.79 on Nov 20, down 9.68% (-$1.37), versus the S&P 500's 3.70% decline. Shares are 44.9% below their 52-week high of $23.21, set on Sep 25, 2026 and 2.3% above the 52-week low of $12.50, near the bottom of the past year's range. ADARx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.75), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ADARx Pharmaceuticals
Company profileADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Li Zhen Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 100
- IPO year
- 2026
- Website
- adarx.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$34.25+167.79%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.74 vs $-0.40
- Surprise
- -335.00%
ADRX news
All ADRX newsADARx Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs ADRX |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs ADRX |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs ADRX |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs ADRX |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs ADRX |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs ADRX |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs ADRX |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs ADRX |
Indexes, lists and sector
ADARx Pharmaceuticals stock FAQ
What is ADARx Pharmaceuticals's stock price today?
ADRX last traded at $12.79 as of Nov 20, 4:00 PM EST, down 9.68% on the day. Prices are delayed at least 15 minutes.
Who is ADARx Pharmaceuticals's CEO?
Dr. Li Zhen Ph.D. is the chief executive officer of ADARx Pharmaceuticals Inc., which has about 100 employees.
What is the ADRX 52-week high?
The 52-week high for ADRX is $23.21 and the 52-week low is $12.50. The stock is currently 44.9% below its high.